These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 21641952)
1. Costs and impact of meningitis epidemics for the public health system in Burkina Faso. Colombini A; Badolo O; Gessner BD; Jaillard P; Seini E; Da Silva A Vaccine; 2011 Jul; 29(33):5474-80. PubMed ID: 21641952 [TBL] [Abstract][Full Text] [Related]
2. [Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997]. da Silva A; Parent du Châtelet I; Beckr Gaye A; Dompnier JP; Seck I Sante; 2003; 13(4):215-23. PubMed ID: 15047438 [TBL] [Abstract][Full Text] [Related]
3. Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso. Colombini A; Trotter C; Madrid Y; Karachaliou A; Preziosi MP Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S473-82. PubMed ID: 26553677 [TBL] [Abstract][Full Text] [Related]
4. Costs for households and community perception of meningitis epidemics in burkina faso. Colombini A; Bationo F; Zongo S; Ouattara F; Badolo O; Jaillard P; Seini E; Gessner BD; Da Silva A Clin Infect Dis; 2009 Nov; 49(10):1520-5. PubMed ID: 19842972 [TBL] [Abstract][Full Text] [Related]
5. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE; Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206 [TBL] [Abstract][Full Text] [Related]
6. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Djingarey MH; Barry R; Bonkoungou M; Tiendrebeogo S; Sebgo R; Kandolo D; Lingani C; Preziosi MP; Zuber PL; Perea W; Hugonnet S; Dellepiane de Rey Tolve N; Tevi-Benissan C; Clark TA; Mayer LW; Novak R; Messonier NE; Berlier M; Toboe D; Nshimirimana D; Mihigo R; Aguado T; Diomandé F; Kristiansen PA; Caugant DA; Laforce FM Vaccine; 2012 May; 30 Suppl 2():B40-5. PubMed ID: 22607898 [TBL] [Abstract][Full Text] [Related]
7. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE; Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028 [TBL] [Abstract][Full Text] [Related]
10. [An epidemic of meningococcal meningitis in the region of Savanes in Togo in 1997: research and control strategies]. Aplogan A; Batchassi E; Yakoua Y; Croisier A; Aleki A; Schlumberger M; Molina S; Sidatt M; Kaninda AV Sante; 1997; 7(6):384-90. PubMed ID: 9503496 [TBL] [Abstract][Full Text] [Related]
11. Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine. LaForce FM; Okwo-Bele JM Health Aff (Millwood); 2011 Jun; 30(6):1049-57. PubMed ID: 21653956 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa. Miller MA; Wenger J; Rosenstein N; Perkins B Pediatr Infect Dis J; 1999 Dec; 18(12):1051-9. PubMed ID: 10608623 [TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study. Yaesoubi R; Trotter C; Colijn C; Yaesoubi M; Colombini A; Resch S; Kristiansen PA; LaForce FM; Cohen T PLoS Med; 2018 Jan; 15(1):e1002495. PubMed ID: 29364884 [TBL] [Abstract][Full Text] [Related]
15. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010. Ouandaogo CR; Yaméogo TM; Diomandé FV; Sawadogo C; Ouédraogo B; Ouédraogo-Traoré R; Pezzoli L; Djingarey MH; Mbakuliyemo N; Zuber PL Vaccine; 2012 May; 30 Suppl 2():B46-51. PubMed ID: 22230584 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of meningitis surveillance before introduction of serogroup a meningococcal conjugate vaccine - Burkina Faso and Mali. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1025-8. PubMed ID: 23254257 [TBL] [Abstract][Full Text] [Related]
17. A vaccine to prevent epidemic meningitis in Africa. Viviani S Lancet Infect Dis; 2013 Mar; 13(3):195-6. PubMed ID: 23427886 [No Abstract] [Full Text] [Related]
18. Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines. Robbins JB; Schneerson R; Gotschlich EC; Mohammed I; Nasidi A; Chippaux JP; Bernardino L; Maiga MA Bull World Health Organ; 2003; 81(10):745-50; discussion 751-5. PubMed ID: 14758435 [TBL] [Abstract][Full Text] [Related]
19. The outbreak of meningitis due to Neisseria meningitidis W135 in 2003 in Burkina Faso and the national response: main lessons learnt. Zombré S; Hacen MM; Ouango G; Sanou S; Adamou Y; Koumaré B; Kondé MK Vaccine; 2007 Sep; 25 Suppl 1():A69-71. PubMed ID: 17630052 [TBL] [Abstract][Full Text] [Related]
20. [Clonal expansion of Neisseria meningitidis W135. Epidemiological implications for the African meningitis belt]. du Châtelet IP; Alonso JM; Taha MK Bull Soc Pathol Exot; 2002 Dec; 95(5):323-4; discussion 324-5. PubMed ID: 12696368 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]